

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	CHANGE OF NAME		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Intranasal Therapeutics, Incorporated		02/11/2009	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	Ikano Therapeutics, Inc.		
Street Address:	250 Pehle Avenue		
Internal Address:	Park 80 West - Plaza Two, Suite 310		
City:	Saddle Brook		
State/Country:	NEW JERSEY		
Postal Code:	07663		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 4			
Property Type	Number	Word Mark	
Serial Number:	77663314	IKANO THERAPEUTICS	
Serial Number:	77663346	IKANO THERAPEUTICS	
Serial Number:	77663391	ITI	
Serial Number:	77663397	ITI	
CORRESPONDENCE DATA			
Fax Number:	(617)523-1231		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
Phone:	617.570.1292		
Email:	tadmin@goodwinprocter.com		
Correspondent Name:	Miriam J. Rovner, Senior Paralegal		
Address Line 1:	Exchange Place, 53 State Street		
Address Line 2:	Goodwin Procter LLP		
Address Line 4:	Boston, MASSACHUSETTS 02109		

CH \$115.00 77663314

ATTORNEY DOCKET NUMBER:	122277-171239
NAME OF SUBMITTER:	Miriam J. Rovner
Signature:	/mjr/
Date:	04/07/2009
Total Attachments: 4 source=Ikano 1 Charter Amendment#page1.tif source=Ikano 1 Charter Amendment#page2.tif source=Ikano 1 Charter Amendment#page3.tif source=Ikano 1 Charter Amendment#page4.tif	

Delaware

PAGE 1

The First State


I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "INTRANASAL THERAPEUTICS, INCORPORATED", CHANGING ITS NAME FROM "INTRANASAL THERAPEUTICS, INCORPORATED" TO "IKANO THERAPEUTICS, INC.", FILED IN THIS OFFICE ON THE ELEVENTH DAY OF FEBRUARY, A.D. 2009, AT 8:34 O'CLOCK A.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.

2907226 8100

090125870




Jeffrey W. Bullock, Secretary of State
AUTHENTICATION: 7129723

DATE: 02-11-09

You may verify this certificate online
at corp.delaware.gov/authver.shtml

TRADEMARK
REEL: 003965 FRAME: 0178

**CERTIFICATE OF AMENDMENT OF
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
INTRANASAL THERAPEUTICS, INCORPORATED**

**Pursuant to Sections 228 and 242
of the General Corporation Law of the State of Delaware**

Intranasal Therapeutics, Incorporated (hereinafter called the "Corporation"), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY:

FIRST: The name of the Corporation is Intranasal Therapeutics, Incorporated. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on June 11, 1998 under the name "Inhalation Technology, Inc." An Amended and Restated Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on July 28, 2006. An Amended and Restated Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on June 4, 2008.

SECOND: That the board of directors of the Corporation, by unanimous written consent duly adopted resolutions in accordance with Sections 141(f) and 242 of the General Corporation Law of the State of Delaware (i) proposing certain amendments to the Corporation's Amended and Restated Certificate of Incorporation, (ii) declaring such amendments to be advisable and in the best interests of the Corporation, and (iii) directing that such amendments be submitted to the stockholders of the Corporation for approval thereby. The resolutions setting forth the amendments and directing that such amendments be submitted to the stockholders of the Corporation are as follows:

RESOLVED: That, subject to stockholder approval, the Corporation amend its Amended and Restated Certificate of Incorporation as filed with the Secretary of State of the State of Delaware, as follows:

Article FIRST of the Amended and Restated Certificate of Incorporation shall be replaced in its entirety by the following:

"FIRST: The name of this corporation is Ikano Therapeutics, Inc. (the "Corporation")"

The first paragraph of Article FOURTH shall be amended and restated in its entirety to read as follows:

“The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i) Six Hundred Thirty Million (630,000,000) shares of Common Stock, \$0.001 par value per share (“Common Stock”), and (ii) One Hundred Seventy One Million (171,000,000) shares of Preferred Stock, \$0.001 par value per share (“Preferred Stock”).”

The first sentence of Part C of Article FOURTH shall be amended and restated to read as follows:

“One Hundred Thirty Five Million (135,000,000) shares of the authorized and unissued Preferred Stock of the Corporation are hereby designated “Series B Preferred Stock” with the following rights, preferences, powers, privileges and restrictions, qualifications and limitations.”

RESOLVED: That the foregoing amendment is hereby recommended to the stockholders of the Corporation as being advisable and in the best interests of the Corporation and its stockholders.

RESOLVED: That the amendment to the Amended and Restated Certificate of Incorporation, as described in the foregoing resolutions, be submitted to the stockholders of the Corporation entitled to vote thereon for its approval in compliance with Section 242 and 228 of the General Corporation Law of the State of Delaware.

THIRD: That the aforesaid amendment was duly adopted in accordance with the provisions of Sections 141(f) and 242 of the General Corporation Law of the State of Delaware and has been consented to in writing by the stockholders of the Corporation in accordance with Sections 228 and 242 of the General Corporation Law of the State of Delaware.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, this Certificate of Amendment has been executed by Peter Young, the Corporation's President and Chief Executive Officer, this 11th day of February, 2009.

INTRANASAL THERAPEUTICS, INCORPORATED

By: /s/ Peter F. Young
Peter F. Young
President and Chief Executive Officer